PARP1 and cancer: Here, therapeutic radionuclides, i.e., α, β-, and auger emitters, were conjugated to PARPis with the goal of effectively inflicting DNA damage on cancer cells, as binding to PARP1 leads to radioactive decay events in close proximity of the DNA.